FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 833 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Seven Centres to form new Cancer Research UK network January 24, 2022 Working Outdoors in the Sunshine May Lower Your Risk of Breast... February 18, 2021 EMA Recommends Extension of Therapeutic Indications for Zanubrutinib October 26, 2022 Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... November 15, 2024 Load more HOT NEWS Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... Sex, intimacy and cancer – That Cancer Conversation Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease...
